Urinary cysteinyl leukotriene E4 level and therapeutic response to montelukast in children with mild obstructive sleep apnea

• DOI: 10.12932/ap0879
• Publication Date: 2017-04-01T11:13:10Z
• Authors: Kanokkarn Sunkonkit; Suchada Sritippay...; Montida Veeravikrom; Jitladda Deerojan...; Nuanchan Prapphal
• Keywords: Therapeutic effect; Leukotriene E4

Antileukotriene has been used for alleviating disease severity in children with adenotonsillar hypertrophy (ATH) and mild obstructive sleep apnea (OSA). Previous study showed the relationship between urinary cysteinyl leukotriene E₄ (uLTE₄) level therapeutic response to montelukast asthmatic adults. However, this never investigated pediatric OSA.To determine uLTE₄ ATH OSA.Children aged 3-15 yrs who had OSA were enrolled. All quality of life (assessed by Thai version OSA-18 QoL questionnaire) levels measured prior start a 6-week course treatment. Overnight polysomnography (PSG) reassessment performed after completing Those demonstrated large improvement mean total score or ≥ 50% decrease apnea-hypopnea index (OAHI) treatment defined as responders.Twenty-six enrolled (mean age 7.5 ± 2.9 yrs, 38.5% male). After montelukast, nine (34.6%) significant improvement. The from responders was higher comparing non-responders (2,952.56 966.9 vs. 978.6 460.8 pg/mg creatinine; p < 0.001). 1,457 creatinine 100% sensitivity 88.2% specificity identifying responders.We found association ULTE4 monteleukast. could predict OSA.